Core Viewpoint - Tian Shi Li Pharmaceutical Group's subsidiary has received approval for a new indication of its recombinant human urokinase for the treatment of acute ischemic stroke, enhancing its product line and market competitiveness [1][3]. Group 1: Drug Information - The drug, recombinant human urokinase (brand name: Pu You Ke), is now approved for thrombolytic treatment of acute ischemic stroke [1]. - It is a first-class biological innovative drug supported by the national "Major New Drug Creation" project during the "11th Five-Year Plan" [1]. - The drug has a specific mechanism that preferentially activates plasminogen on the surface of fibrin, targeting occlusive thrombus while minimizing the risk of bleeding [2]. Group 2: Clinical and Market Impact - The drug's Phase III clinical results indicate that it is non-inferior to the control group for patients with acute ischemic stroke when administered within 4.5 hours of onset, while significantly reducing the risk of intracranial hemorrhage [2]. - The total R&D investment for the acute ischemic stroke indication has reached approximately 32.93 million RMB [3]. - The approval of this new indication expands the company's product offerings in the neurological and psychiatric fields, potentially increasing its market share and competitiveness [3].